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OBJECTIVES: To assess the results of growth hormone on the growth of girls with Turner Syndrome and identify relevant pa-
rameters to improve outcomes. 
METHODS: Growth velocity and final height were studied in a historical cohort of 41 girls, regularly followed up for hormone 
distribution at three referral centers. The influence of oxandrolone and of estrogens on the final height was analyzed. The girls (initial 
chronological age=8.9±3.4years; initial bone age=7.0±3.1years) used 0.19 mg/kg/week of growth hormone for 4.0 ± 2.0 years. 
RESULTS: In the first year, growth velocity increased by 71.5% in 41 girls and 103.4% in those who reached final height (11 
girls). The whole group had a gain in the height SDS of 0.8 ± 0.7 (p<0.01) and for those who reached a final height of 1.0 ± 0.8 
(p<0.01). Final height (143.6 ±6.3 cm) was 3.9 ± 5.3 cm higher than the predicted height, and the height gain occurred before 
estrogen therapy. Oxandrolone had no significant influence on height gain. The significant variables contributing to the final height 
were the duration of growth hormone used and its use prior to starting estrogens, the initial height SDS, and the growth velocity 
during the first year of treatment. 
CONCLUSIONS: We concluded that the use of growth hormone significantly increased the final height, which remained lower than 
the target. Results point to a need for starting growth hormone use as early as possible and to maximize treatment before estrogen 
replacement. It has been observed that even moderate doses of growth hormone may significantly increase early growth velocity. 
KEYWORDS: Growth. Growth velocity. Adult height. Growth hormone. Turner syndrome.
INTRODUCTION
The most common feature of Turner Syndrome (TS) is 
short stature. Without intervention, the patients attain a mean 
adult height approximately 20 cm below that of the control 
female population.
Growth failure has been ascribed to many factors1,2 and 
most studies have not shown evidence of growth hormone and 
IGF-1 deficiencies in pre-pubertal children with TS.3,4 Despite 
this, it has also been observed that treatment with recombinant 
growth hormone (GH) increases growth velocity (GV) in these 
girls.5 TS is one of the conditions worldwide that has well-
established indications for treatment with GH. 
Compared with the height predicted at the beginning of 
treatment or to the height attained by historical control groups 
of patients with TS, GH supplementation was estimated to have 
no effect on adult height in some studies or a moderate effect in 
most. Factors contributing to wide variability in the estimated 
effects of GH supplementation on adult height include differ-
ences in treatment protocols, such as the age of initiation of GH 
therapy, dosing regimen, and adjuvant therapies.6,7
The aim of this study is to assess the effect of GH supple-
mentation on the growth of girls with TS treated at a public 
program responsible for hormone distribution and to analyze 
relevant factors that produce the best outcomes. 
SUBJECTS AND METHODS
All records of TS girls referred for GH treatment, accord-
ing to the protocol established by the Department of Health 
from 1993 to 2004, were assessed.174
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To be included in the program, their diagnosis had to 
be confirmed by karyotype, slow growth rate, and bone age 
(BA) of less than 12.5 years.8 Moreover, the girls could not 
have other diseases that caused short stature.
Patients included in the study (n=41) were girls using GH 
for at least one year. Four girls did not have any growth pro-
moting treatment, except for estrogens, and were followed 
until they reached their final height. They were used as his-
torical controls (HC) in addition to 14 other Brazilian girls 
with TS described in the literature,9 totaling 18 controls. 
According to the program, the girls stopped treatment 
when presenting a BA above 13 years or height of 150 cm. 
Non-compliance or treatment interruption for more than 6 
months, GV less than 3 cm per year while using GH, the oc-
currence of other diseases, or the use of medications that could 
interfere with growth were all reasons for ceasing treatment. 
Among the 41 girls studied, 11 reached final height.
Treatment
The patients were treated with daily subcutaneous injec-
tion of 0.5 IU/kg/week (0.17 mg/kg/week) of GH. Oxan-
drolone was prescribed to patients from two referral centers, 
with doses of 0.0625 mg/kg/day, which were interrupted 
before the sex steroid replacement.
Estrogen replacement was used in patients with no signs 
of puberty at the bone age of 13 years.10
METHODS
During the follow-up period, height was measured every 
quarter using a fixed stadiometer. 
Data on height, expressed in cm and Z score (SDS), 
were compared to the National Center for Health Statistics 
(NCHS) data11 and to the data generated by Lyon et al. for 
patients with TS.12 GV was assessed during the first five 
years of treatment.
Final height (FH) was defined as the most recent reading 
after discontinuation of GH when GV was 1.0 cm per year 
or less.
The projected adult height was based on growth curves 
published by Lyon, assuming that without treatment, the pa-
tient would have had the same Turner standardized height at 
adulthood that she had at baseline.12 The initial height SDS 
of each girl was then compared to the mean height of girls 
suffering from TS without any treatment. This method has 
been shown to be accurate using independent U.S. data.13
Target height (TH) was defined as the mean parental 
height – 6.5 cm.14
The FH was compared with the predicted final height 
(PFH) and with the final height of the HC; the remaining 
height deficit (TH – FH) was also calculated.
This study was approved by the Research Ethics Com-
mittee of the Institution. Forty-one girls were called by 
phone or contacted by mail. Those who were still participat-
ing in the GH program and those responding to the calls 
were examined and had their auxological data assessed, after 
having signed the informed consent.
Statistical analysis
The Student t test for independent samples was used 
to compare the means between groups. To compare means 
within the groups, the paired Student t test was used. Simple 
linear regression analysis was used to stratify pre-treatment 
and treatment variables influencing FH. Rejection of the null 
hypothesis was set at 5% (p<0.05).
RESULTS
Growth velocity 
The chronological age of 41 girls at the initiation of GH 
therapy was 8.9 ± 3.4 years with a bone age (n=39) of 7.0 ± 
3.1 years. The mean duration of GH use (n=41) was 4.0 ± 
2.0 years with a mean dose of 0.19 mg/kg/week.
GV increased significantly in all girls after GH therapy. 
In 41 girls, pre-treatment GV increased from 3.5 ± 1.8 to 
6.0 ± 1.4 cm/year during the first year (71.4%; p=0.00), 
which declined in subsequent years but remaining above 
pre-treatment GV during the first 5 years (Table 1). 
Pre-treatment GV of 11 girls who completed treatment 
was 2.9 ± 1.8 cm/year, increasing to 5.9 ± 1.5 cm/year 
(p=0.00) in the first year. GV decreased in the subsequent 
years but remained greater than that prior to treatment. 
Catch-up growth occurred in the first two years of treatment 
compared to the Lyon curve. Height SDS gain (0.4 ± 1.1 
SD) coincided with a significant GV increase in the first 
two years of treatment as compared to the pre-treatment GV 
(p=0.00) (Figure 1).
Table 1 - Growth velocity in TS girls before and after treatment with GH
Pre-GH Year 1 post-GH Year 2 post-GH Year 3 post-GH Year 4 post-GH Year 5 post-GH
GV (cm/y) (n=41) 3.5 ± 1.8 6.0 ± 1.4  5.2 ± 1.3 5.2 ± 1.3  4.6 ± 1.8 4.3 ± 1.4
GV (cm/y) (n=11) 2.9 ± 1.8 5.9 ± 1.5  5.7 ± 1.0  4.8 ± 1.4 4.0 ± 1.8 3.0 ± 2.3175
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Out of 41 girls, 24 used associated oxandrolone and 17 
used GH exclusively. Table 2 shows that despite a higher pre-
treatment GV of the girls receiving oxandrolone, the increase 
was similar in both groups in the three years following GH 
treatment. Therefore, no benefits of GV were observed with 
the use of oxandrolone. There was no difference in age at 
baseline between the two groups as well as in GH dose. 
According to the Lyon curve, 24 girls using oxandrolone, 
and 17 girls that did not use it grew similarly (p=0.88). 
Final Height 
The characteristics of the 11 TS girls who reached FH are 
depicted in table 3. Mean duration of GH use was 3.6 ± 1.7 
years and the follow-up time from GH cessation to FH was 
2.5 ± 1.7 years. Mean GH dose in the first year of treatment 
was 0.15 mg/kg/week, reaching a peak of 0.18 mg/kg/week 
during the first 5 years. 
Mean FH was 143.6 ± 6.3 cm, corresponding to -3.1 ± 
0.9 SD (NCHS) or 0.5 ± 1.0 SD (Lyon). FH surpassed the 
PFH described by Lyon by 3.9 ± 5.3 cm, which is a signifi-
cant gain in height (p=0.03). 
There was a significant increase in height SDS compared 
to baseline according to NCHS (0.5 ± 0.7 SD, p=0.04) and 
Lyon (1.0 ± 0.8 SD, p=0.00) standards. After GH discontinu-
ation, there was no significant increase in the height of the 
patients followed up, until they reached FH. 
Final height surpassed TH, minus 20 cm, which is in 
agreement with the international pattern 15 by 6.7 ± 6.3 cm, 
resulting in a significant gain in height (p=0.01). The differ-
ence between final height (139.9 ± 7.0 cm) and target height 
(TH = 154.4 ± 5.5) of the Brazilian Historical Controls was 
15.5cm. There was no significant increase in FH of the girls 
studied compared to their TH minus 15.5cm (p=0.27). 
The height deficit of 11 girls who reached FH was 13.3 
Figure 1 - Mean GV increase in TS girls after rhGH compared to initial 
GV
Table 2 - Growth velocity in TS girls before and after treatment with GH alone or associated with oxandrolone (Mean ± 
SD)
Pre-GH (n=37) Year 1 post-GH (n=41) Year 2 post-GH (n=35) Year 3 post-GH (n=22)
Oxa group + GH (cm/y) 4.1 ± 2.5 (n=21) 6.3 ± 1.9 (n=24) 5.3 ± 1.2 (n=24) 5.2 ± 1.4 (n=18)
GH group (cm/y) 2.7 ± 3.0 (n=16) 5.7 ± 1.9 (n=17) 5.1 ± 1.6 (n=11) 5.4 ± 1.0 (n=4)
* p 0.02 0.2 0.7 0.8
*t test comparing the two groups
Table 3 - Characteristics of 11 TS patients who reached final height (Mean ± SD)
Pre-treatment Data at the end of GH Post treatment Height gain p *
CA years 11.5 ±2.2 15.2 ± 1.3 17.7 ± 1.8
BA years  9.1 ± 2.1 (n=10) 13.9 ± 1.0 (n=11)
∆BA/∆CA years 1.08
Height cm 122.4 ± 11 140.1 ± 7.4 143.6 ± 6.3 0.00
Weight SD -1.7 ± 1.1 -1.6 ± 1.3 0.84
Pre-treatment GV  2.9 ± 1.8
TH cm 156.8 ± 5.1
PFH cm (Lyon) 139.6 ± 6.6 3.9± 5.3 0.03
Height SD(NCHS) -3.6 ± 0.8 -3.2 ± 0.9 -3.1 ± 0.9 0.04
Height SD (Lyon)  -0.4± 0.9 0.7 ± 1.1 0.5 ± 1.0 0.00
* Paired t test comparing final to baseline data176
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± 6.3 cm relative to their target height.
Estrogen replacement in 11 girls was started at the age 
of 14.6 ± 1.4 years, after 3.0 ± 2.1 years using GH. While 
using GH before starting estrogens, a significant height in-
crease relative to the Lyon chart was observed (0.9 ± 0.6 SD, 
p=0.00), which was not maintained after initiating estrogen 
replacement until final height was reached (0.1 ± 0.5 SD, 
p=0.66), as shown in figure 2. 
In the simple linear regression analysis, the factors as-
sociated with an increase in final height relative to initial 
height were duration of GH use (p<0.05), duration of GH 
use prior to starting estrogens (p<0.05), the initial height 
SDS (p<0.05), and GV in the first year (p<0.05). 
The factors associated with reaching greater final height 
SDS were the baseline height SDS (p<0.05) and the parental 
target height (p<0.05). That is, the smaller the height deficit 
and the greater the parental target height when the treatment 
was started, the better the outcome for FH. 
DISCUSSION
Reports on the FH of girls with TS treated with GH are 
highly variable. The mean increase by 6.0 cm in final height 
relative to the predicted height (ranging from -0.2 to 16.9 
cm) and the mean FH of 150.3 cm16 still raises concerns 
about the clinical relevance of the treatment. Among the 
problems involving comparative assessments are the consid-
erable differences among study protocols regarding sample 
size, doses, age at the start of the treatment, and the associ-
ated use of estrogens and oxandrolone. The first clinical ran-
domized trial carried out in Canada showed a FH of 147.5 ± 
6.5 cm (TH= 160.7 ± 6.2) with a mean height gain of 7.2 cm. 
The authors concluded that GH supplementation increased 
the adult height of girls with TS and that the benefits of GH 
supplementation needs to be balanced against the cost of 
therapy and the need for daily subcutaneous injections over 
a period of many years.17 A statistically significant increase 
in height during GH use was observed in the present study. 
Despite this, the FH attained by the girls can be considered 
insufficient when compared to that of the general population. 
The girls reached a final height of 143.6 ± 6.3 cm, which 
represented a mean increase of 4 cm relative to the PFH. We 
should bear in mind that lower doses were prescribed for 
these girls compared to most other reports. American FDA 
approved doses are 0.054 mg/kg/d (0.38 mg /kg/week).18 In 
the Canadian study, girls were given 0.30 mg/kg/week.17 
There is evidence that the increase in FH in girls with 
TS depends on age at start of treatment,19 duration of GH 
use6,10,19 and the duration of its use prior to estrogen replace-
ment,10,15,20,21 which are tightly interdependent factors. An as-
sociation between FH and height at the start of the treatment 
was seen,19 as well as with TH.15,19,22 
The GH dose may also influence FH.6,10,19 Studies con-
ducted on patients with either GH deficiency or TS demon-
strated that the response to GH treatment is dependent on 
the dose and on the frequency of GH administration.6,22 Poor 
final outcomes are frequently attributed to the low initial 
dose of GH used. However, in the present study, a significant 
improvement in GV was observed in response to GH and the 
increase in GV in the first year of treatment was similar to 
that reported in studies employing higher initial doses,24,25 
followed further by a rapid decrease, which has also been 
reported.23,24-26 In 11 girls who reached FH, GV accelerated 
103.4% in the first year and 75.8% in the second year of 
treatment as compared to the pre-treatment GV. 
Despite the gradual decline, GV during the first five 
years of treatment was still higher than the pre-treatment GV. 
However, the increase in GV was significant only in the first 
two years due to the decline in the response to GH. This ef-
fect was also reported in studies from the Netherlands24,25 that 
demonstrated an increase in GV by 100% during the first year 
of treatment with GH at a dose of 0.9 IU/kg/week relative to 
pre-treatment GV. A similar increase was observed in the pres-
ent study using a lower GH dose. However, such an increase 
in GV was not maintained during subsequent years of treat-
ment, which has also been reported in the literature.23,26,27 This 
decline was also observed in children with GH deficiency and 
could be overridden by increasing the GH dose 2- to 3-fold.23,28 
Some studies suggested that the GV drop in girls with TS 
could also be compensated by the progressive increase in GH 
doses, reducing the final loss.25,29 Thus, it seems that these girls 
could benefit from an increased dose as GV declines. Taken 
together, this raises the question of whether this should be the 
best way to administer treatment.
Takano30 studied pre-pubertal girls with TS using two 
regimens of GH doses (0.5 and 1.0 IU/kg/week) and verified 
Figure 2 - Influence of estrogen replacement in the growth of the 11 girls 
with TS during rhGH use177
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a significant increase in GV in the first 2 years of treatment 
in the group receiving the higher dose. However, no signifi-
cant differences in GV after the third year and especially, 
on the final height between the two groups after 6 years of 
GH use were observed.5 This suggests that the use of high, 
fixed doses does not prevent the decline in GV and therefore 
would not be recommended. 
In a recently published consensus of the TS study group, 
it was assumed that doses substantially higher than those 
approved by the FDA produce a relatively small gain in final 
height.18 
On the other hand, there is no significant difference be-
tween induced and spontaneous puberty with regard to final 
height,31 but data regarding the appropriate time to induce 
puberty with estrogens are conflicting.20,21,32-34 Height gain 
was observed prior to estrogens and not after they were 
started in our studied population. Chernausek13 showed that 
TS girls who started estrogen replacement at 12 years of age 
had reduced height gain compared to those starting it at the 
age of 15 years. However, the number of years of GH treat-
ment before estrogens was the single most important factor 
for predicting the response to treatment, as also shown by 
other authors.10,20 Van Pareren21 and Reiter20 reported that 
girls with TS who received GH for at least 4 years before 
starting estrogens reached FH within the usual range, even 
with the onset of puberty at a physiological age. 
It is known that at a bone age of 9 years, the difference 
in mean height between TS girls and normal girls is about 
16 cm, a deficit found almost throughout adult life. The in-
ternational literature shows that untreated TS girls reached 
a final height 20 cm shorter than their target height.15,19,22 
Thus, from puberty on, there is little additional height loss 
compared to normal girls, despite the absence of the pubertal 
growth spurt. It is reasonable to think that if the treatment 
with GH was started before this age, the height deficit could 
be reduced prior to the induction of puberty, and the estrogen 
replacement could start at an appropriate time.
Some studies suggest that final height can be normalized 
when treatment begins earlier and when the doses of GH are 
higher and titrated.29,32,33,35 
We demonstrated that the duration, in years of GH use, 
the duration of use before estrogens were started, the initial 
height SDS, and the first year GV were the variables as-
sociated with an increase in height SDS. Catch-up growth 
occurred in the first two years of treatment and prior to 
estrogen replacement. 
The results reported here point to the need for starting 
treatment with GH as early as possible in order to prevent 
further height deterioration and to maximize treatment prior 
to estrogen replacement that could take place during a physi-
ological age. This study showed that the use of GH, even 
in modest doses, may promote a significant increase in the 
initial GV. Further evaluations should be conducted in order 
to determine if increasing the dose as GV decreases may be 
beneficial to the patients. Insufficient GV responses early 
in the treatment may justify the use of higher initial doses. 
Further studies are still needed to clarify these issues. 
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